Liraglutide

Renal Impairment No dose adjustment of liraglutide injection is recommended for patients with renal impairment [see Clinical Pharmacology]. The safety and efficacy of liraglutide injection was evaluated in a 26-week clinical study that included patients with moderate renal impairment (eGFR 30 to 60 mL/min/1.73 m 2 ) [see Clinical Studies].

There is limited experience with liraglutide injection in patients with end stage renal disease.

Hepatic Impairment There is limited experience in patients with mild, moderate or severe hepatic impairment. Therefore, liraglutide injection should be used with caution in this patient population. No dose adjustment of liraglutide injection is recommended for patients with hepatic impairment [see Clinical Pharmacology] .

Important Administration Instructions Inspect visually prior to each injection. Only use if solution is clear, colorless, and contains no particles. Inject liraglutide injection subcutaneously once daily at any time of day, independently of meals. Inject liraglutide injection subcutaneously in the abdomen, thigh or upper arm.

No dosage adjustment is needed if changing the injection site and/or timing. Rotate injection sites within the same region in order to reduce the risk of cutaneous amyloidosis [see Adverse Reactions] . When using liraglutide injection with insulin, administer as separate injections. Never mix. It is acceptable to inject liraglutide injection and insulin in the same body region but the injections should not be adjacent to each other.